TVTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TVTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-07), Travere Therapeutics's current share price is $7.23. Travere Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was $3.78. Travere Therapeutics's Cyclically Adjusted PS Ratio for today is 1.91.
The historical rank and industry rank for Travere Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
During the past years, Travere Therapeutics's highest Cyclically Adjusted PS Ratio was 9.00. The lowest was 1.39. And the median was 5.67.
TVTX's Cyclically Adjusted PS Ratio is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Travere Therapeutics's adjusted revenue per share data for the three months ended in Mar. 2024 was $0.536. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $3.78 for the trailing ten years ended in Mar. 2024.
The historical data trend for Travere Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PS Ratio | Get a 7-Day Free Trial | 6.09 | 4.13 | 2.41 | 2.46 | 2.04 |
For the Biotechnology subindustry, Travere Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Travere Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Travere Therapeutics's Cyclically Adjusted PS Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Travere Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as
Cyclically Adjusted PS Ratio | = | Share Price | / | Cyclically Adjusted Revenue per Share |
= | 7.23 | / | 3.78 | |
= | 1.91 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Travere Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, Travere Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:
Adj_RevenuePerShare | = | Revenue per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 0.536 | / | 131.7762 | * | 131.7762 | |
= | 0.536 |
Current CPI (Mar. 2024) = 131.7762.
Travere Therapeutics Quarterly Data
Revenue per Share | CPI | Adj_RevenuePerShare | |
201406 | 0.210 | 100.560 | 0.275 |
201409 | 0.296 | 100.428 | 0.388 |
201412 | 0.574 | 99.070 | 0.763 |
201503 | 0.572 | 99.621 | 0.757 |
201506 | 0.689 | 100.684 | 0.902 |
201509 | 0.655 | 100.392 | 0.860 |
201512 | 0.763 | 99.792 | 1.008 |
201603 | 0.764 | 100.470 | 1.002 |
201606 | 0.908 | 101.688 | 1.177 |
201609 | 0.918 | 101.861 | 1.188 |
201612 | 0.869 | 101.863 | 1.124 |
201703 | 0.859 | 102.862 | 1.100 |
201706 | 0.994 | 103.349 | 1.267 |
201709 | 1.044 | 104.136 | 1.321 |
201712 | 1.050 | 104.011 | 1.330 |
201803 | 0.969 | 105.290 | 1.213 |
201806 | 1.032 | 106.317 | 1.279 |
201809 | 1.000 | 106.507 | 1.237 |
201812 | 1.060 | 105.998 | 1.318 |
201903 | 0.956 | 107.251 | 1.175 |
201906 | 1.066 | 108.070 | 1.300 |
201909 | 1.033 | 108.329 | 1.257 |
201912 | 1.085 | 108.420 | 1.319 |
202003 | 1.096 | 108.902 | 1.326 |
202006 | 1.082 | 108.767 | 1.311 |
202009 | 1.004 | 109.815 | 1.205 |
202012 | 0.994 | 109.897 | 1.192 |
202103 | 0.843 | 111.754 | 0.994 |
202106 | 0.902 | 114.631 | 1.037 |
202109 | 1.122 | 115.734 | 1.278 |
202112 | -0.623 | 117.630 | -0.698 |
202203 | 0.768 | 121.301 | 0.834 |
202206 | 0.851 | 125.017 | 0.897 |
202209 | 0.438 | 125.227 | 0.461 |
202212 | 0.457 | 125.222 | 0.481 |
202303 | 0.453 | 127.348 | 0.469 |
202306 | 0.785 | 128.729 | 0.804 |
202309 | 0.486 | 129.860 | 0.493 |
202312 | 0.589 | 129.419 | 0.600 |
202403 | 0.536 | 131.776 | 0.536 |
Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Thank you for viewing the detailed overview of Travere Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Jula Inrig | officer: Chief Medical Officer | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130 |
Peter Heerma | officer: Chief Commercial Officer | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130 |
William E. Rote | officer: Senior Vice President, R&D | C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Christopher R. Cline | officer: Chief Financial Officer | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO CA 92130 |
Eric M Dube | director, officer: Chief Executive Officer | 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130 |
Elizabeth E Reed | officer: SVP, GC & Corporate Secretary | 9050 CAMINO SANTA FE, SAN DIEGO CA 92121 |
Sandra Calvin | officer: VP, Corp Controller and CAO | 3611 VALLEY CENTER DRIVE, SUITE 300, SAN DIEGO CA 92130 |
Laura Clague | officer: Chief Financial Officer | 370 PARK RANCH PLACE, ESCONDIDO CA 92025 |
Steve Aselage | director | 6300 DUMBARTON CIRCLE, FREMONT CA 94555 |
Brinkley Ruth Williams | director | C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130 |
Noah L. Rosenberg | officer: Chief Medical Officer | C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170 |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
Neil F. Mcfarlane | officer: Chief Operating Officer | C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130 |
Sandra Poole | director | 830 WINTER STREET, WALTHAM MA 02451 |
Ron Squarer | director | C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066 |
From GuruFocus
By Marketwired • 09-26-2023
By PRNewswire • 06-23-2023
By Marketwired • 08-24-2023
By Marketwired • 09-05-2023
By GlobeNewswire • 07-11-2023
By sperokesalga sperokesalga • 06-08-2023
By Marketwired • 09-11-2023
By PRNewswire • 07-03-2023
By Marketwired • 07-20-2023